Dexcom Raises Full-Year Guidance on Record Margins, Strong U.S. Growth

Dexcom (NASDAQ:DXCM) reported Q3 2026 results exceeding expectations, with revenue of $1.344 billion and non-GAAP EPS of $0.73. The glucose monitoring company raised its full-year guidance across multiple metrics, driven by:

• Gross margins reaching a multi-year high of 65.1%.
• Robust 14% U.S. revenue growth, offsetting slower international expansion.
• Publication of the CONNECT study in NEJM, showcasing strong A1C results.

Shares rose 1.73% after-hours as investors reacted positively to improved profitability and steady execution. [1]